12 assets in Anemia

Therapeutic assets addressing Anemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Anemia	OHSU Knight Cancer Institute	P4	BBB (73)
Luspatercept Anemia	Guangdong Second Provincial General Hospital	P4	BBB (72)
Busulfanum Anemia	Masonic Cancer Center, University of Minnesota	P4	BB (70)
Iron(Ii) Sulphate (1:1), Heptahydrate Anemia	Korea University Guro Hospital	P4	BB (70)
Fludarabine Anemia	Masonic Cancer Center, University of Minnesota	P3	BB (66)
Rituximab Anemia	OHSU Knight Cancer Institute	P3	B (63)
Tacrolimus Anemia	Masonic Cancer Center, University of Minnesota	P2	B (62)
Ibrutinib Anemia	National Cancer Institute (NCI)	P3	B (60)
Iron Isomaltoside Anemia	China-Japan Friendship Hospital	P2	CCC (53)
Vipivotide Tetraxetan Anemia	M.D. Anderson Cancer Center	P2	CCC (53)
Zilurgisertib Anemia	Incyte Corporation	P1/2	CC (47)
Umbilical Cord Derived Mesenchymal Stem Cells Exosomes Anemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1	CC (43)